Market News

Gauging Brainstorm’s Risk Factors

Brainstorm Cell Therapeutics (BCLI) is a leading provider of cellular treatments for neurodegenerative diseases.

Let’s take a look at what has changed in the company’s key risk factors that investors should know. (See Brainstorm stock charts on TipRanks)

Brainstorm Cell Risk Factors

According to the new TipRanks Risk Factors tool, Brainstorm’s main risk category is Tech & Innovation, which accounts for 28% of the total 50 risks identified.

Since June 2021, Brainstorm has updated its risk profile to introduce one new risk factor, under the Macro & Political category.

The company said, “The coronavirus outbreak has caused disruptions to our business, including our preclinical and clinical development activities.”

Here, Brainstorm emphasizes that the company has endured a lot of stress and volatility in its stock price since the outbreak of the coronavirus. The pandemic has had an influence on the company’s operations, including preclinical and clinical trials. Furthermore, the impact of this crisis on the company’s business is unknown, and it could continue to impede its operations.

On the brighter side, the overall sector average for the Finance & Corporate risk factor is 28.9%, higher than the average risks in that category for Brainstorm, which stands at 20%.

Brainstorm’s Financial Performance

Brainstorm’s Q2 general and administrative expenses increased 47.1%, to $2.5 million, while net research and development expenses decreased 36.8%, to $3.6 million on a year-over-year basis.

The company reported a GAAP net loss of $0.17 per share in the second quarter, versus $0.25 per share in the year-ago quarter.

Wall Street’s Take

The stock has picked up a rating from one analyst in the past three months.

Maxim Group analyst Jason McCarthy assigned a Buy rating on BCLI, and a price target of $12. This implies 247.8% upside potential to current levels.

McCarthy comments, “Brainstorm remains well-funded as it works with regulators to determine the path to a Biologics License Application (BLA) in ALS, and to advance NurOwn in multiple sclerosis (MS).”

Related News :
ICL Procures €250 Million Sustainability Linked Loan
VEON Announces Sale of Russian Tower Assets For $970M; Street Says Buy
LGI Homes Closes 776 Homes in August

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed